These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

450 related articles for article (PubMed ID: 16879967)

  • 1. Emerging roles of pseudokinases.
    Boudeau J; Miranda-Saavedra D; Barton GJ; Alessi DR
    Trends Cell Biol; 2006 Sep; 16(9):443-52. PubMed ID: 16879967
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ATP and MO25alpha regulate the conformational state of the STRADalpha pseudokinase and activation of the LKB1 tumour suppressor.
    Zeqiraj E; Filippi BM; Goldie S; Navratilova I; Boudeau J; Deak M; Alessi DR; van Aalten DM
    PLoS Biol; 2009 Jun; 7(6):e1000126. PubMed ID: 19513107
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activation of the tumour suppressor kinase LKB1 by the STE20-like pseudokinase STRAD.
    Baas AF; Boudeau J; Sapkota GP; Smit L; Medema R; Morrice NA; Alessi DR; Clevers HC
    EMBO J; 2003 Jun; 22(12):3062-72. PubMed ID: 12805220
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BCR/ABL-negative chronic myeloproliferative disorders: JAK2 mutation and beyond.
    Chang CC
    Arch Pathol Lab Med; 2006 Aug; 130(8):1123-5. PubMed ID: 16879012
    [No Abstract]   [Full Text] [Related]  

  • 5. Detection of the single hotspot mutation in the JH2 pseudokinase domain of Janus kinase 2 in bone marrow trephine biopsies derived from chronic myeloproliferative disorders.
    Bock O; Büsche G; Koop C; Schröter S; Buhr T; Kreipe H
    J Mol Diagn; 2006 May; 8(2):170-7. PubMed ID: 16645202
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Myeloproliferative disorders carrying the t(8;9) (PCM1-JAK2) translocation.
    Bousquet M; Brousset P
    Hum Pathol; 2006 Apr; 37(4):500; author reply 500-2. PubMed ID: 16564930
    [No Abstract]   [Full Text] [Related]  

  • 7. Allosteric protein kinase regulation by pseudokinases: insights from STRAD.
    Rajakulendran T; Sicheri F
    Sci Signal; 2010 Mar; 3(111):pe8. PubMed ID: 20197543
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diagnostic assays for the JAK2 V617F mutation in chronic myeloproliferative disorders.
    Greiner TC
    Am J Clin Pathol; 2006 May; 125(5):651-3. PubMed ID: 16707363
    [No Abstract]   [Full Text] [Related]  

  • 9. [A recurrent mutation of the JAK2 gene in chronic myeloproliferative disorders].
    Berger R
    Pathol Biol (Paris); 2006 May; 54(4):182-4. PubMed ID: 16084028
    [No Abstract]   [Full Text] [Related]  

  • 10. The V617F JAK2 mutation is uncommon in cancers and in myeloid malignancies other than the classic myeloproliferative disorders.
    Scott LM; Campbell PJ; Baxter EJ; Todd T; Stephens P; Edkins S; Wooster R; Stratton MR; Futreal PA; Green AR
    Blood; 2005 Oct; 106(8):2920-1. PubMed ID: 16204151
    [No Abstract]   [Full Text] [Related]  

  • 11. A unifying mutation in chronic myeloproliferative disorders.
    Goldman JM
    N Engl J Med; 2005 Apr; 352(17):1744-6. PubMed ID: 15858182
    [No Abstract]   [Full Text] [Related]  

  • 12. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders.
    Baxter EJ; Scott LM; Campbell PJ; East C; Fourouclas N; Swanton S; Vassiliou GS; Bench AJ; Boyd EM; Curtin N; Scott MA; Erber WN; Green AR;
    Lancet; 2005 Mar 19-25; 365(9464):1054-61. PubMed ID: 15781101
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of the LKB1-STRAD-MO25 complex.
    Boudeau J; Scott JW; Resta N; Deak M; Kieloch A; Komander D; Hardie DG; Prescott AR; van Aalten DM; Alessi DR
    J Cell Sci; 2004 Dec; 117(Pt 26):6365-75. PubMed ID: 15561763
    [TBL] [Abstract][Full Text] [Related]  

  • 14. JAK2 V617F mutation in classic chronic myeloproliferative diseases: a report on a series of 349 patients.
    Vizmanos JL; Ormazábal C; Larráyoz MJ; Cross NC; Calasanz MJ
    Leukemia; 2006 Mar; 20(3):534-5. PubMed ID: 16408096
    [No Abstract]   [Full Text] [Related]  

  • 15. A JAK2 mutation in myeloproliferative disorders: pathogenesis and therapeutic and scientific prospects.
    James C; Ugo V; Casadevall N; Constantinescu SN; Vainchenker W
    Trends Mol Med; 2005 Dec; 11(12):546-54. PubMed ID: 16271512
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New insights into the pathogenesis of JAK2 V617F-positive myeloproliferative disorders and consequences for the management of patients.
    Villeval JL; James C; Pisani DF; Casadevall N; Vainchenker W
    Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):341-51. PubMed ID: 16810610
    [TBL] [Abstract][Full Text] [Related]  

  • 17. JAK2 V617F: a single mutation in the myeloproliferative group of disorders.
    McLornan D; Percy M; McMullin MF
    Ulster Med J; 2006 May; 75(2):112-9. PubMed ID: 16755940
    [No Abstract]   [Full Text] [Related]  

  • 18. Structure of the LKB1-STRAD-MO25 complex reveals an allosteric mechanism of kinase activation.
    Zeqiraj E; Filippi BM; Deak M; Alessi DR; van Aalten DM
    Science; 2009 Dec; 326(5960):1707-11. PubMed ID: 19892943
    [TBL] [Abstract][Full Text] [Related]  

  • 19. JAK2T875N is a novel activating mutation that results in myeloproliferative disease with features of megakaryoblastic leukemia in a murine bone marrow transplantation model.
    Mercher T; Wernig G; Moore SA; Levine RL; Gu TL; Fröhling S; Cullen D; Polakiewicz RD; Bernard OA; Boggon TJ; Lee BH; Gilliland DG
    Blood; 2006 Oct; 108(8):2770-9. PubMed ID: 16804112
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Refractory anemia with ringed sideroblasts associated with marked thrombocytosis harbors JAK2 mutation and shows overlapping myeloproliferative and myelodysplastic features.
    Wang SA; Hasserjian RP; Loew JM; Sechman EV; Jones D; Hao S; Liu Q; Zhao W; Mehdi M; Galili N; Woda B; Raza A
    Leukemia; 2006 Sep; 20(9):1641-4. PubMed ID: 16871284
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 23.